Primary Immune Deficiency Clinical Trials 2023

Primary Immune Deficiency Clinical Trials 2023

Primary Immune Deficiency research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in primary immune deficiency clinical trials today.

Primary Immune Deficiency Clinical Trials

Here are the 0 most popular medical studies for primary immune deficiency

Popular filter options for primary immune deficiency trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to primary immune deficiency

What are the top hospitals conducting primary immune deficiency research?

Houston is a city that not only boasts a thriving medical community but also serves as a hub for cutting-edge research in primary immune deficiency. Houston Methodist Hospital, one of the leading institutions in the area, has initiated an active clinical trial focused on this condition. While it may seem like just one trial, it represents an important step forward in understanding and treating primary immune deficiency. Similarly, Texas Children's Hospital, located right next to Houston Methodist Hospital, is also conducting its own active clinical trial dedicated to this rare disorder. Together, these hospitals are spearheading efforts to advance knowledge and develop innovative treatments for primary immune deficiency.

Meanwhile, in St. Petersburg, Florida, the University of South Florida is joining the ranks with their own ongoing clinical trial for primary immune deficiency. Although they have yet to record any previous trials specifically targeting this condition until now—highlighting another aspect of their dedication to groundbreaking research.

Primary immune deficiency refers to a group of disorders characterized by compromised or absent immune system function from birth or early childhood onwards. This means individuals with these conditions are more susceptible to infections and may struggle with recurrent illnesses that can be severe or difficult to manage.

By conducting clinical trials dedicated exclusively to studying primary immune deficiencies at these renowned medical centers across different locations such as Houston and St.Petersburg; researchers can collect valuable data on potential therapies while offering patients opportunities for advanced treatments that could significantly improve their quality of life.

These hospitals' commitment towards exploring novel treatment options leads us closer towards better understanding and management strategies that could positively impact not only individuals living with primary immune deficiencies but also potentially shed light on broader aspects of immunology research benefiting countless others facing similar challenges worldwide

Which are the best cities for primary immune deficiency clinical trials?

Houston, Texas and St. Petersburg, Florida emerge as the leading cities for primary immune deficiency clinical trials. Houston boasts 2 active trials examining promising treatments like CliniMACS. Meanwhile, St. Petersburg hosts 1 ongoing trial exploring potential breakthroughs such as Bacteriophage therapy. These cities offer individuals with primary immune deficiencies access to cutting-edge research that could revolutionize treatment options and improve their quality of life.

Which are the top treatments for primary immune deficiency being explored in clinical trials?

When it comes to primary immune deficiency, one treatment stands out in current clinical trials: CliniMACS. Despite being relatively new on the scene since its listing in 2023, this promising therapy is already making waves with one active trial dedicated solely to primary immune deficiency. As researchers delve deeper into understanding and addressing this condition, CliniMACS offers hope for patients seeking effective treatments that can potentially revolutionize their lives.

What are the most recent clinical trials for primary immune deficiency?

The most recent clinical trials for primary immune deficiency offer promising advancements in the field. One noteworthy trial focuses on a novel treatment approach using gene therapy to address underlying genetic defects causing immune deficiencies. Another study explores the efficacy of a specific medication in boosting the weakened immune system of patients with primary immunodeficiency disorders. These trials highlight the ongoing efforts to develop targeted therapies and improve outcomes for individuals living with primary immune deficiency, bringing hope for better management and quality of life in the future.

What primary immune deficiency clinical trials were recently completed?

Recently, several clinical trials investigating primary immune deficiencies have reached significant milestones, representing promising advancements in the field. Notably, a trial for Uproleselan sponsored by Washington University School of Medicine was completed in October 2021. In September 2021, the National Cancer Institute concluded a trial for mRNA-1273. Additionally, AgenTus Therapeutics successfully completed their agenT-797 study in January 2021. These achievements highlight the commitment of researchers and offer hope to patients grappling with primary immune deficiencies as they strive to develop improved treatments.